Advertisement
Home »

Inherited blood cancer predisposition through altered transcription elongation.

Jan 15, 2024

ABOUT THE CONTRIBUTORS

  • Jiawei Zhao

    Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Center for Cancer Immunology, Faculty of Pharmaceutical Sciences, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences (CAS), Shenzhen, China. Electronic address: jw.zhao3@siat.ac.cn.

    Liam D Cato

    Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.

    Uma P Arora

    Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.

    Erik L Bao

    Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.

    Samuel C Bryant

    Broad Institute of MIT and Harvard, Cambridge, MA, USA.

    Nicholas Williams

    Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK; UK and MRC-Wellcome Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.

    Yuemeng Jia

    Harvard Stem Cell Institute, Cambridge, MA, USA; Stem Cell Program, Boston Children’s Hospital, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.

    Seth R Goldman

    Nascent Transcriptomics Core, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

    Jyoti Nangalia

    Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK; UK and MRC-Wellcome Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.

    Michael A Erb

    Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.

    Seychelle M Vos

    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.

    Scott A Armstrong

    Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.

    Vijay G Sankaran

    Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA. Electronic address: sankaran@broadinstitute.org.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement